The Texas Diagnostic and Devices Company Award supports the ongoing research and development of diagnostic tests and devices to treat, detect, diagnose, monitor, and assist in the treatment of cancer.
Donor Name: Cancer Prevention & Research Institute of Texas
State: Texas
County: All Counties
Type of Grant: Grant
Deadline: 06/30/2023
Grant Duration: 36 months
Details:
CPRIT’s Product Development Research Program Priorities
In addition to overarching principles that include scientific excellence, impact on cancer, and increasing the state’s life science infrastructure, CPRIT’s Oversight Committee establishes annual priorities for each of its 3 programs. The priorities guide CPRIT in the development of RFAs and the evaluation of applications considered for awards.
The Product Development Research Program’s priorities for FY 2024 are as follows:
- Funding novel projects that offer therapeutic or diagnostic benefits; ie, disruptive technologies
- Funding projects addressing large or challenging unmet medical needs
- Investing in early-stage projects when private capital is least available
- Stimulating commercialization of technologies developed at Texas entities
- Supporting new company formation in Texas or attracting promising companies to Texas that will recruit staff with life science expertise, especially experienced C-level staff
- Providing appropriate return on Texas taxpayer investment.
Funding Stage for Texas Diagnostic and Devices Company Awards
Funding available through this RFA supports the ongoing research and development of diagnostic tests and devices to treat, detect, diagnose, monitor, and assist in the treatment of cancer. Relevant areas include:
- Devices and assays for cancer detection, diagnosis, prognosis, monitoring, treatment and prediction of response or resistance to treatment
- Markers for cancer prevention and control, companion diagnostic to a therapy
- Development of diagnostic tests to distinguish high-risk early lesions
Generally, at the time that an applicant applies to CPRIT pursuant to this RFA, the company has developed a commercial prototype of the device or a pictorial representation of the functional components/elements of the device. With respect to diagnostics, the company has developed assays that work on human samples and whose importance is well justified for development into clinical assays. The applicant should be working toward submitting an Investigational Device Exemption (IDE) or a 510(k) or Premarketing Approval (PMA) and is typically within one year from filing an IDE (or later stage work.) Potential applicants that are not at or near this stage of product development should consider applying for a Texas Seed Company Award.
With appropriate justification, companies may use CPRIT funds to support studies that establish preclinical proof of concept, product validation, design, production, manufacturing and development, and clinical studies demonstrating safety and efficacy.
Grant Period
Maximum 36 months.
Allowable Expenses
Companies may use CPRIT funds for expenses associated only with activities directly related to the specific project that CPRIT is funding. Allowable expenses include the following:
- Salary and fringe benefits
- Research supplies
- Equipment
- Clinical trial expenses
- Intellectual property (IP) acquisition and protection
- External consultants and service providers
- Travel in support of the project
- Other appropriate research and development costs, subject to certain limitations set forth by Texas law.
Eligibility Criteria
CPRIT considers a company to be Texas-based if it fulfills at least 4 of the following criteria:
- The US headquarters are physically located in Texas
- The chief executive officer resides in Texas
- A majority of the company’s personnel, including at least 2 other C-level employees (or equivalent), reside in Texas
- Manufacturing activities take place in Texas
- At least 90% of grant award funds are paid to individuals and entities in Texas, including salaries and personnel costs for employees and contractors
- At least 1 clinical trial site is in Texas
- The company collaborates with a medical research organization in Texas, including a public or private institution of higher education.
For more information, visit CPRIT.
